Epinephrine Administration in Sublingual Immunotherapy Tablet Trials is Rare in Children
Anaphylaxis is a rare event associated with sublingual immunotherapy (SLIT)-tablet treatment. Epinephrine is a first-line treatment for anaphylaxis. The epinephrine use in pediatric subjects with allergic rhinitis/conjunctivitis participating in SLIT-tablet clinical trials is described. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Remi Gagnon, Michael Blaiss, Graham Roberts, Tomokazu Matsuoka, Susanne Halken, Ryuji Azuma, Hendrik Nolte Source Type: research
A Replicate Phase III Clinical Trial to Assess the Reproducibility of Efficacy and Safety of Reproxalap Ophthalmic Solution (0.25%) Compared to Vehicle in Participants With Seasonal Allergic Conjunctivitis (AC) Using the Environmental Exposure Chamber (EEC)
Reproxalap is a reactive aldehyde species inhibitor which demonstrated good safety and significant reduction in AC signs/symptoms in the first Phase III study conducted from 2019-2021 (NCT04207736). A replicate phase III study was conducted in 2021-2023 in an EEC, to confirm the reproducibility of Reproxalap ’s efficacy (NCT05234554). (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Anne Marie Salapatek, Yasmeen Goyal, Christy Fredrick, Gaayathrry Thurairajah, Patricia Couroux, Todd Brady Source Type: research
Safety Profile of Grass, Ragweed, and House Dust Mite Sublingual Immunotherapy Tablets in Children and Adolescents
Allergy immunotherapy is the only disease-modifying treatment for allergic rhinitis and/or conjunctivitis (AR/C). This analysis evaluated the safety of grass, ragweed, and house dust mite (HDM) sublingual immunotherapy (SLIT)-tablets for AR/C in children and adolescents across the clinical development program. (Source: Journal of Allergy and Clinical Immunology)
Source: Journal of Allergy and Clinical Immunology - February 1, 2024 Category: Allergy & Immunology Authors: Michael Blaiss, David Bernstein, Tomokazu Matsuoka, Susanne Halken, Ryuji Azuma, Hendrik Nolte Source Type: research
Podcast on Cross-speciality Perspectives on Practical Management of Atopic Dermatitis-Associated Ocular Surface Diseases
AbstractThere is a growing awareness among dermatology providers of ocular comorbidities in patients with the chronic inflammatory skin disease atopic dermatitis (AD). For example, the prevalence of ocular surface diseases (OSD) such as conjunctivitis is higher in patients with AD than in the general population, and the use of some AD treatments may be associated with OSD. In a recent review published in the Journal of the American Academy of Dermatology, dermatologists and ophthalmologists provided an overview of the different types, etiology, pathophysiology, and practical management of OSD associated with AD. This rev...
Source: Dermatology and Therapy - February 1, 2024 Category: Dermatology Source Type: research
Dupilumab for the treatment of moderate and severe atopic dermatitis: real-life experience
CONCLUSIONS: Dupilumab is an effective disease-modifying drug for patients with moderate to severe atopic dermatitis. The effects of treatment in real life are consistent with those demonstrated in clinical trials.PMID:38282886 | PMC:PMC10809831 | DOI:10.5114/ada.2023.133818 (Source: Advances in Dermatology and Allergology)
Source: Advances in Dermatology and Allergology - January 29, 2024 Category: Dermatology Authors: Jowita Sroka-Tomaszewska Barabara Buli ńska Aleksandra Wilkowska Roman J Nowicki Magdalena Trzeciak Source Type: research
